TeamDrive
RUS

NovaMedica appoints Rustam Iksanov as R&D Vice President

11 August 2017

Moscow, August 11, 2017 – Rustam Iksanov, who used to hold one of the managerial positions in Valenta Pharma, has been appointed as R&D Vice President of pharmaceutical company NovaMedica.

“The level of tasks, that we set  for our R&D division, is a real challenge within the current situation in the Russian pharmaceutical market. I am confident that Rustam Iksanov, who possesses great experience in development of commercially successful products in different companies, will cope with these tasks perfectly”, noted Alexander Kuzin, CEO of NovaMedica.

“I am glad that I have the opportunity to join NovaMedica team which within a very short time has managed to gain prominent results in the market. I am inspired by the task to structure work under R&D projects and creation of new drug products which will be basis of the product portfolio of our company”, said Rustam Iksanov.

Rustam Iksanov has been working in the Russian pharmaceutical market for more than 17 years. Before joining NovaMedica he took the position of M&A Director in Valenta Pharm where he managed  the business development of Gastroenterology division. He developed strategic scenarios of product portfolio development, managed pipeline projects and was responsible for search of potential targets for acquisition (products, developments, companies), preparation and implementation of deals.

Earlier Rustam was Vice President for Strategic Development in Akrikhin (Polpharma), he also hold managerial positions in the field of development products and product portfolio in Izvariono Pharma (Ferring Pharmaceuticals) and Nizhpharm (Stada). Before that he held classes at the Nizhny Novgorod State Medical Academy and worked as a physician.  

Rustam graduated with honors from the Nizhny Novgorod State Medical Academy. In addition, he undertook special programs devoted to commercialization of technologies in the Russian Presidential Academy of National Economy and to pharmaceutical management and economics in the Peoples’ Friendship University of Russia.

Rustam is co-developer of more than 10 inventions in the field of pharmacy, which are protected by patents of the Russian Federation. 

NovaMedica is a modern Russian pharmaceutical company founded in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC (RUSNANO controls 50% of NovaMedica shares through the venture fund RusnanoMedInvest). NovaMedica's strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceuticals products and technologies, as well as at development and implementation of own R&D projects.

NovaMedica owns intellectual property rights within Russia and the CIS on innovative developments from the portfolio of the RusnanoMedInvest venture fund. Today NovaMedica’s pipeline already has 36 IP for preparations for antiviral and anti-inflammatory therapy, treatment of ophthalmic diseases and epilepsy, innovative technologies for detection of oncological and infectious diseases. Also NovaMedica is working on creation of a number of its own products. R&D department of the company plans to develop about 15 innovative drugs until 2022. These are drugs for treatment of diseases in the field of gastroenterology, pain management, neurology, ophthalmology and rheumatology.

In April 2017, NovaMedica opened the Technological Center with a complex of R&D laboratories and pilot production in Technopolis “Moscow”. The Technological Center has the latest technological capabilities previously unavailable in the Russian pharmaceutical industry. The company also has a developed infrastructure for promoting and selling pharmaceutical products.

Read more about us on www.novamedica.com, follow us on Facebook and LinkedIn

Contacts for media: Tatiana Albaut  , +79175451241


Previous publication Next publication

Media Center

  • 17 November 2017

    FDA Overhauls Inspection Process and Field Operations

    To ensure the quality and safety of drugs, biologics, and medical products more efficiently and effectively, FDA is making significant changes in its plant inspection program, including more attention to imports and to foreign producers of drugs for American consumers. An aim is to target manufacturing oversight to more high-risk operations and free up resources for greater scrutiny of foreign facilities in the process.

  • 16 November 2017

    EMA and EUnetHTA published a new joint work plan

    The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) have published a joint work plan outlining key areas of collaboration for the next three years.

  • 16 November 2017

    U.S. approves digital pill that tracks when patients take it

    U.S. regulators have approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology.

  • 15 November 2017

    MIT scientists propose a safer way to edit genes with CRISPR

    The gene editing system CRISPR-Cas9 has generated excitement for its potential use in eliminating disease-causing irregularities in DNA. But most CRISPR systems rely on viruses to carry Cas9 components into cells, where they then go to work cutting DNA.

Read more